Unlocking a New Era of Automated Protein and Antibody Purification with AmMag™ Quatro Solutions: Scalable, Flexible, Validated
Efficient purification of proteins and antibodies is critical for drug target identification, drug candidate development, and fundamental research. However, traditional chromatography method can be labor-intensive, time-consuming, and may compromise yield due to resin structure limitations. Magnetic beads, on the other hand, can deliver high purity and recovery of purification, consistent performance across samples, and simplified workflow directly from cell culture without clarification. The AmMag™ Quatro Automated System Series - including the Mini 1100, and ProAb 1300 - in combination with a wide range of compatible AmMag™ magnetic beads, offers a fully automated solution for mini to midi scale purification. In this presentation, we will take deep review of the system on its scalable throughput, high yield and reproducible results, flexible protocol set-up, and how it minimizes hands-on time and accelerate productivity.
Take your protein and antibody purification workflow to the next level with the validated and easy-to-use AmMag™ Quatro platform.
Can't make it in person? Request a virtual demo here

A Data-Driven AI Approach for Multi-Parameter Antibody Therapeutic Design
Join this talk from our external speaker, Dr. Weian Zhao, the CEO of Aureka Biotechnologies, to learn how GenScript’s TurboCHOTM service has helped them with their research.
Aureka Biotechnologies develops life-saving antibody therapeutics at scale, powered by generative models and high-throughput proprietary data generation platform.
This presentation will showcase the design of differentiated antibody therapeutics that would otherwise be difficult to identify with traditional discovery methods, including agonists, epitope-specific design, and pH-dependent recycling antibodies. 

Next-Gen Antibodies, Simplified: Accelerating Discovery Through Smart Integration
Multifunctional antibodies and immunocytokines are redefining the frontiers of immunotherapy by enabling precise and synergistic targeting of complex disease mechanisms.
In this session, we will explore how GenScript's comprehensive suite of discovery and development services, including gene synthesis, antibody engineering, protein expression, early developability assessments, and functional bioassays, supports the efficient design and optimization of these next-generation biologics.
Learn how GenScript provides the innovation, integration, and technical depth needed to accelerate breakthroughs in multifunctional antibody therapeutics.

Enhancing Antibody Quality and Developability with Optimized Protein Solutions
Antibody-based therapeutics continue to advance as powerful tools in immunotherapy, yet their development is often hindered by challenges in expression, purification, and early-stage optimization. Achieving high yield, purity, and developability requires integrated solutions that streamline workflows and reduce uncertainty.
GenScript provides a comprehensive portfolio of products and services encompassing protein expression platforms, purification strategies, and optimization approaches that enable researchers to efficiently progress from gene to functional antibody.
By combining innovation with proven technologies, these solutions enhance antibody quality, improve developability profiles, and help accelerate timelines toward preclinical and clinical success.

Driving Efficiency in Antibody Production: Strategies for Optimizing Expression and Purification
The antibody therapeutics revolution is driving innovations from monoclonal to bispecific antibodies (BsAbs), though challenges remain in achieving high-yield expression, ensuring downstream suitability, and preventing BsAb mispairing. GenScript’s proprietary TurboCHO™ platform addresses these hurdles by delivering rapid, high-yield production (as fast as 5 BD) from milligram to kilogram scale.
With added signal peptide optimization and purification strategies, TurboCHO™ ensures consistency and performance, accelerating antibody discovery.